Biden ex­ec­u­tive or­der lifts ban on us­ing march-in rights to low­er drug costs

4 years ago
FDA+

House com­mit­tees kick off in­ves­ti­ga­tion in­to how Bio­gen's Aduhelm won ap­proval

4 years ago
Pharma
FDA+

In search of a post-Tec­fidera hit for MS, Bio­gen fol­lows Sanofi, Roche down the BTK path — and bets $125M cash on a ...

4 years ago
Deals
China

CMS kicks off 9-month process on whether to lim­it cov­er­age to Bio­gen's new Alzheimer's drug

4 years ago
Pharma

David Liu takes the wraps off $315M launch round for Prime Med­i­cine and new CRISPR tech that gave Bob Nelsen a 'holy ...

4 years ago
Financing
Startups

Zan­tac man­u­fac­tur­ers off the hook af­ter judge dis­miss­es neg­li­gence and fail­ure-to-warn claims in class-ac­tion law­suit

4 years ago
FDA+

FDA adds sec­ond warn­ing to J&J's Covid-19 vac­cine on da­ta link­ing it to rare nerve con­di­tion

4 years ago
FDA+
Coronavirus

Af­ter month­s­long lull, Big Phar­ma should be ready to pounce on M&A as mar­ket set­tles — an­a­lysts

4 years ago
Deals

In mul­ti­ple myelo­ma show­down, J&J adds an­oth­er feath­er to Darza­lex's cap

4 years ago
R&D
FDA+

Af­ter ques­tions sur­round­ing fund­ing, Re­i­Thera re­veals high an­ti­body re­sponse for Covid-19 jab in PhII study

4 years ago
Coronavirus

WHO is­sues new guide­lines for gene edit­ing; Doud­na-backed Cari­bou launch­es its first al­lo­gene­ic CAR-T tri­al

4 years ago
News Briefing

Switch­ing fo­cus in the brain, re­searchers her­ald a pos­si­ble gene ther­a­py break­through in treat­ing an ul­tra-rare ...

4 years ago
R&D
Cell/Gene Tx

Branch­ing out from di­a­betes? No­vo Nordisk shells out the big bucks for Prothena's AT­TR amy­loi­do­sis pipeline

4 years ago
Deals

As 5 more biotechs file their IPOs, one Nas­daq of­fi­cial does­n't see mo­men­tum slow­ing down any­time soon

4 years ago
Financing

Biden sets a 45-day count­down for 'com­pre­hen­sive' plan to tack­le drug pric­ing — while cham­pi­oning some fa­mil­iar ...

4 years ago
Pharma

Covid-19 roundup: In­otrem loads up on French fund­ing to take sep­tic shock can­di­date to the next stage; Bel­gian woman ...

4 years ago
Coronavirus

Storm brews around Aduhelm as FDA re­quests probe; Dis­sect­ing pipeline dis­as­ters; Bob Nelsen is go­ing Re­al­ly Big; and ...

4 years ago
Weekly

Aim­ing to re­bound from blun­ders years ago, Celldex touts a Phase Ib win with sights set on Xo­lair

4 years ago
R&D

Astel­las and Seagen's Pad­cev wins full FDA ap­proval, notch­ing ex­pand­ed la­bel in tough-to-crack urothe­lial can­cer

4 years ago
Pharma
FDA+

Bay­er takes SGLT2 hope­fuls head on with FDA ap­proval for new kid­ney dis­ease drug

4 years ago
Pharma
FDA+

Janet Wood­cock calls for in­de­pen­dent in­ves­ti­ga­tion in­to Bio­gen and FDA re­la­tion­ships in un­prece­dent­ed move

4 years ago
FDA+

With TransCode go­ing pub­lic, in­dus­try sur­pass­es $10B IPO mark; Galect­in's in­hibitor shows PhIb suc­cess in can­cer ...

4 years ago
News Briefing

Flag­ship takes a rare knock as cell re­place­ment start­up based on Bob Langer tech gets slapped with clin­i­cal hold

4 years ago
FDA+

Great Danes: Two Nordic biotechs name their chief ex­ec­u­tives; Ax­el Hoos bids adieu to Glax­o­SmithK­line, be­comes CEO of ...

4 years ago
Peer Review
First page Previous page 668669670671672673674 Next page Last page
A service from the Financial Times